John Kollins, Satsuma Pharmaceuticals CEO
Satsuma backs away from commercial efforts after migraine candidate fails to hit primary endpoint
Two years ago, Satsuma Pharmaceuticals had a Phase III failure for a nasal drug intended to treat migraines, and now it seems the company has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
